Cargando…

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma

Background: Although the introduction of protease inhibitor bortezomib (BTZ) and immunomodulatory agent lenalidomide has led to improved outcomes in patients with multiple myeloma (MM), the disease remains incurable. Gambogenic acid (GNA), a polyprenylated xanthone isolated from the traditional Chin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Runzhe, Zhang, Hongming, Liu, Ping, Wu, Xue, Chen, Baoan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381173/ https://www.ncbi.nlm.nih.gov/pubmed/28382147 http://dx.doi.org/10.7150/jca.17657

Ejemplares similares

Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21
por: Liu, Ping, et al.
Publicado: (2017)

Gambogenic acid inhibits the proliferation of small-cell lung cancer cells by arresting the cell cycle and inducing apoptosis
por: Huang, Tingting, et al.
Publicado: (2019)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
por: Chen, Runzhe, et al.
Publicado: (2017)

Gambogenic Acid Kills Lung Cancer Cells through Aberrant Autophagy
por: Mei, Wang, et al.
Publicado: (2014)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

Gambogenic Acid Induces Endoplasmic Reticulum Stress in Colorectal Cancer via the Aurora A Pathway
por: Liu, Cheng, et al.
Publicado: (2021)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
por: Ding, Kaixi, et al.
Publicado: (2022)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis
por: Chen, Runzhe, et al.
Publicado: (2017)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
por: Yao, Yao, et al.
Publicado: (2016)

COVID-19 Transmission Within a Family Cluster in Yancheng, China
por: Zhang, Hongming, et al.
Publicado: (2020)

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
por: Chen, Runzhe, et al.
Publicado: (2015)

Gambogenic acid exerts anticancer effects in cisplatin-resistant non-small cell lung cancer cells
por: Shen, Daofu, et al.
Publicado: (2020)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
por: Kozalak, Gül, et al.
Publicado: (2023)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis
por: Zhang, Jing, et al.
Publicado: (2015)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Expression of the SARS-CoV-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer
por: Zhang, Hongming, et al.
Publicado: (2020)

Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL
por: Bui, Hang Thi Thuy, et al.
Publicado: (2019)

A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
por: Kim, Youngwoon, et al.
Publicado: (2012)

Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
por: Ambur, Austin B, et al.
Publicado: (2021)

Primary malignant lymphoma of the uterus and broad ligament: a case report and review of literature
por: Chen, Runzhe, et al.
Publicado: (2015)

Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD
por: Zhang, Hongming, et al.
Publicado: (2015)

Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway
por: Jin, Yulong, et al.
Publicado: (2019)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
por: Leng, Yun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37s8uh96anm3b600b7jvaoi7qa